The world of biotechnology is a thrilling, high-stakes rollercoaster. It’s an industry driven by scientific breakthroughs and billion-dollar dreams, but one where the path to success is often treacherous. From the staggering costs that can reach hundreds of millions of dollars, to fierce competition and the long, uncertain journey toward drug approval, biotech is not for the faint of heart. And even when the science is sound, there’s one major hurdle that continues to derail clinical progress: patient enrollment.

Enter Clinical Enrollment (CE), a revolutionary agency that refuses to let recruitment bottlenecks become the death knell of innovation. In a landscape where most vendors get paid regardless of results, CE stands out for one striking reason: they only charge for successful enrollments. That’s right, no retainers, no ad fees, no empty promises. Just real patients in real trials, or they don’t get paid.

And they deliver. Consistently.

The CE Method: A Full-Stack Solution to Enrollment

So, what exactly does Clinical Enrollment do differently?

For starters, they go beyond traditional marketing or database scraping. CE creates a customized digital sphere of influence around every clinical site, resulting in an average of 4.6 million impressions per trial. Their digital strategy is not just about volume—it’s about precision. By blending sophisticated targeting with emotion-driven messaging, they reach and resonate with the right patients, not just any patients.

The process is streamlined and fast. Once a potential candidate expresses interest online, they receive a phone call within 15 minutes. This is followed by an in-depth screening by dedicated Patient Advocates, trained with fully IRB-approved scripts. These advocates aren’t just reading off a checklist—they’re walking patients through complex inclusion/exclusion criteria with care and clarity.

And it doesn’t stop there. CE also retrieves Electronic Health Records (EHR) within 3–5 days and delivers them to clinical sites via a secure digital portal. Weekly calls with each site ensure that feedback loops remain tight and site needs are constantly evaluated.

In essence, Clinical Enrollment acts as an extension of the sponsor’s team, optimizing patient pipelines while freeing sites from operational overload.

Results That Speak for Themselves

Clinical Enrollment’s track record is not just promising, it’s game-changing. Here’s what their average study performance looks like:

• 10,000+ patient screenings
  
  
• 47 enrollments per trial (Phase 2 average)
  
  
• 18% reduction in screen fail rate
  
  
• 57-day average reduction in recruitment timeline
  
  
• 3x increase in patient screening volume
  
  
• 300% growth in therapeutic areas served within a year
  
  

It’s this level of measurable, repeatable success that allows CE to absorb the recruitment risk. They’re not hoping the right patients show up, they’re making sure of it.

The Personal Mission Behind the Model

But perhaps the most compelling part of the Clinical Enrollment story is its origin.

Bryan Manning, the founder of CE, was born with a rare genetic eye condition called Stargardt’s disease. As he grew older, Bryan discovered a heartbreaking truth: a clinical trial that could have helped treat his condition failed, not because the science wasn’t promising, but because it didn’t enroll enough patients.

For Bryan, this wasn’t just a missed opportunity, it was a wake-up call. He founded Clinical Enrollment with a clear purpose: to ensure that no promising trial ever fails again due to poor enrollment. That mission, rooted in personal experience and empathy, remains the heartbeat of the company.

Moving the Needle by Moving the Risk

While the biotech sector continues to face immense volatility, CE’s model offers a new kind of certainty, one where sponsors only pay for actual results. In a business full of what-ifs, that’s a rare and welcome promise.

In the high-risk, high-reward world of drug development, Clinical Enrollment is turning enrollment from a gamble into a guarantee. For sponsors chasing life-changing therapies, partnering with CE isn’t just a strategy, it’s a safeguard.

And perhaps, a revolution in the making.